{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:46:40Z","timestamp":1777045600729,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,23]]},"DOI":"10.7759\/cureus.60924","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T16:02:34Z","timestamp":1716480154000},"source":"Crossref","is-referenced-by-count":1,"title":["CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Systemic Autoimmune Diseases"],"prefix":"10.7759","author":[{"given":"Ananya Reddy","family":"Cingireddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianna","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Wuthrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirudh Reddy","family":"Cingireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-812102-3.00003-8","article-title":"General features of autoimmune disease","author":"Davidson A","year":"2020","unstructured":"Davidson A, Diamond B. General features of autoimmune disease. The Autoimmune Diseases (Sixth Edition). Academic Press, Cambridge, MA; 2020. 17-44. 10.1016\/B978-0-12-812102-3.00003-8"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller FW","year":"2023","unstructured":"Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023, 80:102266. 10.1016\/j.coi.2022.102266","journal-title":"Curr Opin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/728574","article-title":"Systemic autoimmune diseases","volume":"2013","author":"Shi G","year":"2013","unstructured":"Shi G, Zhang J, Zhang Z, Zhang X. Systemic autoimmune diseases. Clin Dev Immunol. 2013, 2013:10.1155\/2013\/728574","journal-title":"Clin Dev Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1249500","article-title":"Novel and potential future therapeutic options in systemic autoimmune diseases","volume":"15","author":"Balogh L","year":"2024","unstructured":"Balogh L, Ol\u00e1h K, S\u00e1nta S, Majerhoffer N, N\u00e9meth T. Novel and potential future therapeutic options in systemic autoimmune diseases. Front Immunol. 2024, 15:10.3389\/fimmu.2024.1249500","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.08.003","article-title":"New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies","volume":"150","author":"Doglio M","year":"2022","unstructured":"Doglio M, Alexander T, Del Papa N, Snowden JA, Greco R. New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies. J Allergy Clin Immunol. 2022, 150:1289-301. 10.1016\/j.jaci.2022.08.003","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky DS","year":"2023","unstructured":"Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023, 19:509-24. 10.1038\/s41581-023-00720-1","journal-title":"Nat Rev Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/antib13010010","article-title":"Immunotherapy strategy for systemic autoimmune diseases: betting on CAR-T cells and antibodies","volume":"13","author":"Chasov V","year":"2024","unstructured":"Chasov V, Zmievskaya E, Ganeeva I, et al.. Immunotherapy strategy for systemic autoimmune diseases: betting on CAR-T cells and antibodies. Antibodies (Basel). 2024, 13:10. 10.3390\/antib13010010","journal-title":"Antibodies (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1184937","article-title":"CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions","volume":"3","author":"Abraham AR","year":"2023","unstructured":"Abraham AR, Maghsoudlou P, Copland DA, Nicholson LB, Dick AD. CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions. Front Ophthalmol. 2023, 3:10.3389\/fopht.2023.1184937","journal-title":"Front Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller F","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al.. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024, 390:687-700. 10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos D","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, et al.. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021, 385:567-9. 10.1056\/NEJMc2107725","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen A","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, et al.. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022, 28:2124-32. 10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang L","year":"2019","unstructured":"Zhang L, Sosinowski T, Cox AR, et al.. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes. J Autoimmun. 2019, 96:50-8. 10.1016\/j.jaut.2018.08.004","journal-title":"J Autoimmun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann C","year":"2023","unstructured":"Bergmann C, M\u00fcller F, Distler JH, et al.. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023, 82:1117-20. 10.1136\/ard-2023-223952","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sj\u00f6gren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng L","year":"2023","unstructured":"Sheng L, Zhang Y, Song Q, et al.. Concurrent remission of lymphoma and Sj\u00f6gren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Front Immunol. 2023, 14:1298815. 10.3389\/fimmu.2023.1298815","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02086-1","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study","volume":"58","author":"Wang J","year":"2023","unstructured":"Wang J, Alkrekshi A, Dasari S, Lin HC, Elantably D, Armashi AR. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study. Bone Marrow Transplant. 2023, 58:1223-8. 10.1038\/s41409-023-02086-1","journal-title":"Bone Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T\u00a0cells","author":"Motte J","year":"2024","unstructured":"Motte J, Sgodzai M, Schneider-Gold C, et al.. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T\u00a0cells. Neuron. 2024, 10.1016\/j.neuron.2024.04.014","journal-title":"Neuron"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt W","year":"2024","unstructured":"Merkt W, Freitag M, Claus M, et al.. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis. 2024, 83:543-6. 10.1136\/ard-2023-225174","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza M","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021, 22:7652. 10.3390\/ijms22147652","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache U","year":"2023","unstructured":"Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treating autoimmune diseases. RMD Open. 2023, 9:e002907. 10.1136\/rmdopen-2022-002907","journal-title":"RMD Open"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B2200256","article-title":"Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches","volume":"23","author":"Gu T","year":"2022","unstructured":"Gu T, Zhu M, Huang H, Hu Y. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J Zhejiang Univ Sci B. 2022, 23:793-811. 10.1631\/jzus.B2200256","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu X","year":"2019","unstructured":"Xu X, Sun Q, Liang X, et al.. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019, 10:2664. 10.3389\/fimmu.2019.02664","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the utoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)","volume":"11","author":"Sandler RD","year":"2020","unstructured":"Sandler RD, Tattersall RS, Schoemans H, et al.. Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the utoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020, 11:524. 10.3389\/fimmu.2020.00524","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah NN","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019, 16:372-85. 10.1038\/s41571-019-0184-6","journal-title":"Nat Rev Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603237","article-title":"Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment?","volume":"11","author":"Sadeqi Nezhad M","year":"2020","unstructured":"Sadeqi Nezhad M, Seifalian A, Bagheri N, Yaghoubi S, Karimi MH, Adbollahpour-Alitappeh M. Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment?. Front Immunol. 2020, 11:603237. 10.3389\/fimmu.2020.603237","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5727516","article-title":"Immunotherapy deriving from CAR-T cell treatment in autoimmune diseases","volume":"2019","author":"Chen Y","year":"2019","unstructured":"Chen Y, Sun J, Liu H, Yin G, Xie Q. Immunotherapy deriving from CAR-T cell treatment in autoimmune diseases. J Immunol Res. 2019, 2019:5727516. 10.1155\/2019\/5727516","journal-title":"J Immunol Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie G","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020, 59:102975. 10.1016\/j.ebiom.2020.102975","journal-title":"EBioMedicine"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: a new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti SA","year":"2022","unstructured":"Beheshti SA, Shamsasenjan K, Ahmadi M, Abbasi B. CAR Treg: a new approach in the treatment of autoimmune diseases. Int Immunopharmacol. 2022, 102:108409. 10.1016\/j.intimp.2021.108409","journal-title":"Int Immunopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241396-cd19-chimeric-antigen-receptor-car-t-cell-therapy-for-systemic-autoimmune-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T16:02:40Z","timestamp":1716480160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241396-cd19-chimeric-antigen-receptor-car-t-cell-therapy-for-systemic-autoimmune-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.60924","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}